(d)-β-Hydroxybutyrate Inhibits Adipocyte Lipolysis via the Nicotinic Acid Receptor PUMA-G
Andrew K.P. TaggartJukka KeroXiaodong GanTian‐Quan CaiKang ChengMarc C. IppolitoNing RenRebecca KaplanKenneth WuTsuei-Ju WuLan JinChen LiawRuoping ChenJeremy G. RichmanDaniel T. ConnollyStefan OffermannsSamuel D. WrightM. Gerard Waters
588
Citation
23
Reference
10
Related Paper
Citation Trend
Abstract:
As a treatment for dyslipidemia, oral doses of 1–3 grams of nicotinic acid per day lower serum triglycerides, raise high density lipoprotein cholesterol, and reduce mortality from coronary heart disease (Tavintharan, S., and Kashyap, M. L. (2001) Curr. Atheroscler. Rep. 3, 74–82). These benefits likely result from the ability of nicotinic acid to inhibit lipolysis in adipocytes and thereby reduce serum non-esterified fatty acid levels (Carlson, L. A. (1963) Acta Med. Scand. 173, 719–722). In mice, nicotinic acid inhibits lipolysis via PUMA-G, a Gi/o-coupled seven-transmembrane receptor expressed in adipocytes and activated macrophages (Tunaru, S., Kero, J., Schaub, A., Wufka, C., Blaukat, A., Pfeffer, K., and Offermanns, S. (2003) Nat. Med. 9, 352–355). The human ortholog HM74a is also a nicotinic acid receptor and likely has a similar role in anti-lipolysis. Endogenous levels of nicotinic acid are too low to significantly impact receptor activity, hence the natural ligands(s) of HM74a/PUMA-G remain to be elucidated. Here we show that the fatty acid-derived ketone body (d)-β-hydroxybutyrate ((d)-β-OHB) specifically activates PUMA-G/HM74a at concentrations observed in serum during fasting. Like nicotinic acid, (d)-β-OHB inhibits mouse adipocyte lipolysis in a PUMA-G-dependent manner and is thus the first endogenous ligand described for this orphan receptor. These findings suggests a homeostatic mechanism for surviving starvation in which (d)-β-OHB negatively regulates its own production, thereby preventing ketoacidosis and promoting efficient use of fat stores. As a treatment for dyslipidemia, oral doses of 1–3 grams of nicotinic acid per day lower serum triglycerides, raise high density lipoprotein cholesterol, and reduce mortality from coronary heart disease (Tavintharan, S., and Kashyap, M. L. (2001) Curr. Atheroscler. Rep. 3, 74–82). These benefits likely result from the ability of nicotinic acid to inhibit lipolysis in adipocytes and thereby reduce serum non-esterified fatty acid levels (Carlson, L. A. (1963) Acta Med. Scand. 173, 719–722). In mice, nicotinic acid inhibits lipolysis via PUMA-G, a Gi/o-coupled seven-transmembrane receptor expressed in adipocytes and activated macrophages (Tunaru, S., Kero, J., Schaub, A., Wufka, C., Blaukat, A., Pfeffer, K., and Offermanns, S. (2003) Nat. Med. 9, 352–355). The human ortholog HM74a is also a nicotinic acid receptor and likely has a similar role in anti-lipolysis. Endogenous levels of nicotinic acid are too low to significantly impact receptor activity, hence the natural ligands(s) of HM74a/PUMA-G remain to be elucidated. Here we show that the fatty acid-derived ketone body (d)-β-hydroxybutyrate ((d)-β-OHB) specifically activates PUMA-G/HM74a at concentrations observed in serum during fasting. Like nicotinic acid, (d)-β-OHB inhibits mouse adipocyte lipolysis in a PUMA-G-dependent manner and is thus the first endogenous ligand described for this orphan receptor. These findings suggests a homeostatic mechanism for surviving starvation in which (d)-β-OHB negatively regulates its own production, thereby preventing ketoacidosis and promoting efficient use of fat stores. Ketone bodies (acetone, acetoacetate (AcAc), 1The abbreviations used are: AcAc, acetoacetate; (d)-β-OHB, (d)-β-hydroxybutyrate; NEFA, non-esterified fatty acid; GTPγS, guanosine 5′-O-(3-thiotriphosphate). 1The abbreviations used are: AcAc, acetoacetate; (d)-β-OHB, (d)-β-hydroxybutyrate; NEFA, non-esterified fatty acid; GTPγS, guanosine 5′-O-(3-thiotriphosphate).and (d)-β-OHB) are produced in the liver from acetyl-CoA derived from β-oxidation of fatty acids (7Laffel L. Diabetes/Metabolism Res. Rev. 1999; 15: 412-426Crossref PubMed Google Scholar). AcAc and (d)-β-OHB are small water-soluble carboxylic acids that are important energy sources for the brain and other tissues during prolonged fasting (10Cahill G.F. N. Engl. J. Med. 1970; 282: 668-675Crossref PubMed Google Scholar). In humans, the serum concentration of (d)-β-OHB is typically ∼50 μm after a meal, rises to ∼0.2–0.4 mm after an overnight fast, reaches ∼1–2 mm after 2–3 days of fasting, and plateaus at ∼6–8 mm upon prolonged starvation (7Laffel L. Diabetes/Metabolism Res. Rev. 1999; 15: 412-426Crossref PubMed Google Scholar, 8Fukao T. Lopaschuk G.D. Mitchell G.A. Prostaglandins Leukotrienes Essent. Fatty Acids. 2004; 70: 243-251Abstract Full Text Full Text PDF PubMed Scopus (254) Google Scholar, 9Senior B. Loridan L. Nature. 1968; 219: 83-84Crossref PubMed Scopus (55) Google Scholar, 11Owen O.E. Reichard Jr., G.A. Isr. J. Med. Sci. 1975; 11: 560-570PubMed Google Scholar). β-OHB infusion into rats (12Bates M.W. Linn L.C. Metabolism. 1976; 25: 685-695Abstract Full Text PDF PubMed Scopus (10) Google Scholar), pancreatomized dogs (13Bjorntorp P. Schersten T. Am. J. Physiol. 1967; 212: 683-687Crossref PubMed Scopus (32) Google Scholar), and humans (9Senior B. Loridan L. Nature. 1968; 219: 83-84Crossref PubMed Scopus (55) Google Scholar, 14Van Hove J.L. Grunewald S. Jaeken J. Demaerel P. Declercq P.E. Bourdoux P. Niezen-Koning K. Deanfeld J.E. Leonard J.V. Lancet. 2003; 361: 1433-1435Abstract Full Text Full Text PDF PubMed Scopus (82) Google Scholar) lowers serum NEFAs in vivo, and β-OHB inhibits lipolysis in primary rat (15Bjorntorp P. J. Lipid Res. 1966; 7: 621-626Abstract Full Text PDF PubMed Google Scholar, 16Bjorntorp P. Metabolism. 1966; 15: 191-193Abstract Full Text PDF PubMed Scopus (9) Google Scholar) or bovine (17Metz S.H. Lopes-Cardozo M. van den Bergh S.G. FEBS Lett. 1974; 47: 19-22Crossref PubMed Scopus (22) Google Scholar) adipocytes, whereas AcAc does not. The fact that these effects are similar to those of nicotinic acid and that both β-OHB and nicotinic acid are small carboxylic acids led us to investigate whether ketone bodies are HM74a agonists. Materials—With the exception of Acifran and lithium (dl)-β-OHB, all compounds tested were from Sigma. Acifran was synthesized by chemists at Arena Pharmaceuticals, and lithium (dl)-β-OHB was made by titrating free (dl)-β-OHB acid (Sigma) with LiOH by chemists at Merck. [35S]GTPγS (1160 Ci/mmol) was from Amersham Biosciences, and [5,6-3H]nicotinic acid (50 Ci/mmol) was from American Radiolabeled Chemical (St. Louis, MO). Molecular Cloning—HM74a and HM74 were cloned by PCR using human genomic DNA as a template and the following primers, GCTGGAGCATTCACTAGGCGAG (sense for HM74a), AGATCCTGGTTCTTGGTGACAATG (antisense for HM74a), GGAGAATTCACTAGGCGAGGCGCTCCATC (sense for HM74), and GGAGGATCCAGGAAACCTTAGGCCGAGTCC (antisense for HM74). PUMA-G was cloned using mouse genomic DNA as template, the sense primer AGATCCACTCATGAGCAAGTCAGACC, and the antisense primer CCTTCTTGTCATAGTAACTTAACGAG. For the generation of stable cell lines, 5 × 106 CHO-K1 cells were transfected with 12 μg of plasmid DNA (pCDNA3.1, Invitrogen) containing either HM74a, HM74, or PUMA-G expressed from the cytomegalovirus promoter. Two days after transfection, the growth medium was supplemented with 400 μg/ml G418 to select for antibiotic-resistant cells. Clonal CHO-K1 cell lines that stably express HM74, HM74a, or PUMA-G were selected based on the ability of nicotinic acid (HM74a and PUMA-G) or S711589 (an Arena HM74-specific agonist; data not shown) to inhibit forskolin-induced cAMP production. Calcium Mobilization—CHO-K1 cells expressing an NFAT-β-lactamase reporter and the promiscuous Gα subunit Gqi5 (kind gift of K. Sullivan, Merck Research Laboratories) were stably transfected with either empty vector (pCDNA3.1, Invitrogen) or vector expressing PUMA-G, HM74a, or HM74. Cells were seeded at 10,000 cells/well in 384-well culture plates and grown overnight at 37 °C, 5% CO2 in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, 2 mm l-glutamine, 10 mm HEPES, pH 7.4, 0.1 mm MEM non-essential amino acids solution, 1 mm sodium pyruvate, 0.6 mg/ml hygromycin B, 0.5 mg/ml zeocin, and 1 mg/ml geneticin (BD Biosciences). Cells were washed four times with Hanks' balanced salt solution containing 10 mm HEPES, pH 7.4, and loaded with calcium-sensitive dye by incubating with an equal volume of Molecular Devices calcium assay kit loading buffer at 37 °C for 1 h. Calcium response in the fluorometric imaging plate reader assay was measured according to the directions from Molecular Devices. [35S]GTPγS Binding Assay—Membranes from untransfected CHO-K1 cells or cells stably expressing PUMA-G, HM74a, or HM74 (20 μg/assay) were diluted in assay buffer (20 mm HEPES, pH 7.4, 100 mm NaCl, 10 mm MgCl2) in Wallac Scintistrip plates and preincubated with test compounds diluted in assay buffer containing 40 μm GDP (final [GDP] was 10 μm) for ∼10 min before addition of [35S]GTPγS to 0.3 nm. To measure the agonist activity of free acids, rather than sodium salts (Table I), the HEPES concentration was increased to 60 mm; this increase had no effect on the EC50 of nicotinic acid (data not shown). Binding was allowed to proceed for 1 h before centrifuging the plates at 4000 rpm for 15 min at room temperature and subsequent counting in a Packard TopCount scintillation counter. Non-linear regression analysis of the binding curves was performed in GraphPad Prism version 4.Table ILigand-induced [35S]GTPγS binding to membranes from CHO cells expressing PUMA-G, HM74α, or HM74CompoundEC50PUMA-GHM74aHM74μmNicotinic acid0.04 ± 0.0030.10 ± 0.005>100aSome compounds displayed activity at the highest concentration tested but not over a full dose response from which an EC50 could be determined. Therefore, the EC50 for these compounds is denoted as greater than the highest concentration tested.Acifran0.36 ± 0.031.13 ± 0.067.04 ± 0.6Lithium (dl)-β-hydroxybutyrate727 ± 40793 ± 60>25,000Sodium (d)-β-hydroxybutyrate318 ± 37767 ± 57>25,000Sodium (l)-β-hydroxybutyrate684 ± 1191662 ± 382>25,000Lithium acetoacetate>25,000>25,000>25,000AcetoneInactiveInactiveInactiveSodium (dl)-α-hydroxybutyrate>10,000Inactive>10,000Sodium lactate>10,000InactiveInactiveSodium acetate (C2)>10,000>10,000InactiveSodium propionate (C3)>10,000>10,000InactiveSodium butyrate (C4)702 ± 1081590 ± 211InactivePentanoic acid (C5)166 ± 33402 ± 51>10,000Sodium hexanoate (C6)133 ± 15451 ± 91995 ± 246Heptanoic acid (C7)730 ± 1322066 ± 300120 ± 23Sodium octanoate (C8)288 ± 40755 ± 8273 ± 12Sodium decanoate (C10)>10,000>10,000>10,000Oleic acid (C18:1)InactivebFatty acids with >10 carbons were tested at 10 μm only.InactiveInactiveLinoleic acid (C18:2)InactiveInactiveInactiveLinolenic acid (C18:3)InactiveInactiveInactiveArachidonic acid (C20:4)InactiveInactiveInactiveEicosapentaenoic acid (C20:5)InactiveInactiveInactiveDocosahexanoic acid (C22:6)InactiveInactiveInactivea Some compounds displayed activity at the highest concentration tested but not over a full dose response from which an EC50 could be determined. Therefore, the EC50 for these compounds is denoted as greater than the highest concentration tested.b Fatty acids with >10 carbons were tested at 10 μm only. Open table in a new tab [3H]Nicotinic Acid Binding Competition Assay—Assays were performed with the same preparations of membrane used for the [35S]GTPγS assay. Equilibrium binding of [3H]nicotinic acid was done with membranes (30 μg/assay) and test compounds diluted in assay buffer (20 mm HEPES, pH 7.4, 1 mm MgCl2, and 0.01% CHAPS) in a total volume of 200 μl. After 4 h at room temperature, reactions were filtered through Packard Unifilter GF/C plates using a Packard Harvester and washed eight times with 200 μl of ice-cold binding buffer. Nonspecific binding was determined in the presence of 250 μm unlabeled nicotinic acid. Competitive binding assays were performed in the presence of 50 nm [3H]nicotinic acid. In Vitro Lipolysis—Isolation of mouse primary epididymal adipocytes and in vitro determination of NEFA release was performed according to the method of Rodbell as adapted by Tunaru et al. (3Tunaru S. Kero J. Schaub A. Wufka C. Blaukat A. Pfeffer K. Offermanns S. Nat. Med. 2003; 9: 352-355Crossref PubMed Scopus (657) Google Scholar, 23Rodbell M. J. Biol. Chem. 1964; 239: 375-380Abstract Full Text PDF PubMed Google Scholar). To ask whether β-OHB is a ligand for HM74a, we used Chinese hamster ovary (CHO) cells that stably express the chimeric G-protein α subunit Gqi5 (18Conklin B.R. Farfel Z. Lustig K.D. Julius D. Bourne H.R. Nature. 1993; 363: 274-276Crossref PubMed Scopus (606) Google Scholar) and harbor either a control vector or vectors that expresses either HM74a or its paralog HM74, which is 95% identical at the amino acid level to HM74a but has ∼1000-fold less affinity for nicotinic acid (4Wise A. Foord S.M. Fraser N.J. Barnes A.A. Elshourbagy N. Eilert M. Ignar D.M. Murdock P.R. Steplewski K. Green A. Brown A.J. Dowell S.J. Szekeres P.G. Hassall D.G. Marshall F.H. Wilson S. Pike N.B. J. Biol. Chem. 2003; 278: 9869-9874Abstract Full Text Full Text PDF PubMed Scopus (460) Google Scholar, 5Soga T. Kamohara M. Takasaki J. Matsumoto S. Saito T. Ohishi T. Hiyama H. Matsuo A. Matsushime H. Furuichi K. Biochem. Biophys. Res. Commun. 2003; 303: 364-369Crossref PubMed Scopus (285) Google Scholar). Use of Gqi5 allows the normally Gi/o-coupled HM74 and HM74a to signal via the Gq pathway leading to Ca+2 mobilization. Nicotinic acid elicited Ca+2 mobilization only in cells expressing HM74a (Fig. 1A). In contrast, Acifran, an agonist on both HM74 and HM74a (4Wise A. Foord S.M. Fraser N.J. Barnes A.A. Elshourbagy N. Eilert M. Ignar D.M. Murdock P.R. Steplewski K. Green A. Brown A.J. Dowell S.J. Szekeres P.G. Hassall D.G. Marshall F.H. Wilson S. Pike N.B. J. Biol. Chem. 2003; 278: 9869-9874Abstract Full Text Full Text PDF PubMed Scopus (460) Google Scholar), elicited a response from both receptors demonstrating that HM74 was functional and could be used as a specificity control in this assay. Given that ketone bodies can reach millimolar concentrations in serum, we tested these compounds at 15 mm. Both (d)- and (l)-β-OHB, but not acetoacetate or free acetone, elicited a Ca+2 response in cells expressing HM74a but not HM74. Whereas the d-isomer of β-OHB is the sole form encountered in high concentrations physiologically (7Laffel L. Diabetes/Metabolism Res. Rev. 1999; 15: 412-426Crossref PubMed Google Scholar), both d- and l-isomers have been shown to inhibit lipolysis in vitro (17Metz S.H. Lopes-Cardozo M. van den Bergh S.G. FEBS Lett. 1974; 47: 19-22Crossref PubMed Scopus (22) Google Scholar), consistent with the results shown here. Similar results were observed for cells expressing murine PUMA-G (data not shown). Next, we determined the half-maximal concentration (EC50) of β-OHB required to stimulate receptor-mediated guanine nucleotide exchange on Gα using a [35S]GTPγS binding assay with membranes prepared from untransfected CHO cells or CHO cells stably expressing either mouse PUMA-G, human HM74a, or HM74 (Fig. 1B and Table I). Nicotinic acid stimulated [35S]GTPγS binding only in membranes from cells expressing HM74a (EC50 104 ± 5 nm) or the mouse ortholog PUMA-G (EC50 = 43 ± 3 nm), whereas Acifran was active on all three receptors (EC50 = 1127 ± 59 nm for HM74a, 358 ± 30 nm for PUMA-G, and 7039 ± 598 nm for HM74). Racemic (dl)-β-OHB also showed some degree of activity on all receptors; however, it was more potent on HM74a (EC50 = 0.8 ± 0.06 mm) and its ortholog PUMA-G (EC50 = 0.7 ± 0.04 mm) than on HM74. The EC50 for the l-enantiomer was ∼2-fold higher than that of the physiologically relevant d-enantiomer (Table I). Both the sodium and lithium salts of β-OHB were active, indicating that the anion is the active component. Moreover, sodium salts of other small monocarboxylic acids with similar pKa values to β-OHB (α-hydroxybutyrate and lactate) were not significantly active in this assay (Table I). At high concentrations, lithium acetoacetate, but not acetone or lithium chloride, elicited [35S]GTPγS binding to all three receptors but not to membranes from untransfected cells, suggesting that acetoacetate is a weak agonist of these receptors. Short-chain fatty acids were recently identified as ligands for the G-protein-coupled receptor GPR41, which is, like HM74a/PUMA-G, expressed in adipocytes (19Le Poul E. Loison C. Struyf S. Springael J.Y. Lannoy V. Decobecq M.E. Brezillon S. Dupriez V. Vassart G. Van Damme J. Parmentier M. Detheux M. J. Biol. Chem. 2003; 278: 25481-25489Abstract Full Text Full Text PDF PubMed Scopus (1100) Google Scholar, 20Xiong Y. Miyamoto N. Shibata K. Valasek M.A. Motoike T. Kedzierski R.M. Yanagisawa M. Proc. Natl. Acad. Sci. U. S. A. 2004; 101: 1045-1050Crossref PubMed Scopus (526) Google Scholar, 21Brown A.J. Goldsworthy S.M. Barnes A.A. Eilert M.M. Tcheang L. Daniels D. Muir A.I. Wigglesworth M.J. Kinghorn I. Fraser N.J. Pike N.B. Strum J.C. Steplewski K.M. Murdock P.R. Holder J.C. Marshall F.H. Szekeres P.G. Wilson S. Ignar D.M. Foord S.M. Wise A. Dowell S.J. J. Biol. Chem. 2003; 278: 11312-11319Abstract Full Text Full Text PDF PubMed Scopus (1579) Google Scholar). Given their similarity to β-OHB, we determined whether small fatty acids are ligands for HM74a/PUMA-G. Indeed, a structure-activity relationship was observed for fatty acids of varying chain length (Table I), with pentanoic (C5) and hexanoic (C6) acids being the most active on HM74a (C5, EC50 = 402 ± 51 μm; C6, EC50 = 451 ± 91 μm) and PUMA-G (C5, EC50 = 166 ± 33 μm; C6, EC50 = 133 ± 15 μm). HM74 has affinity for slightly longer chain length fatty acids, with a peak of activity centered on octanoic acid (C8, EC50 = 73 ± 12 μm; Table I). However, it is unlikely that these small fatty acids reach sufficient concentrations in serum to activate these receptors (19Le Poul E. Loison C. Struyf S. Springael J.Y. Lannoy V. Decobecq M.E. Brezillon S. Dupriez V. Vassart G. Van Damme J. Parmentier M. Detheux M. J. Biol. Chem. 2003; 278: 25481-25489Abstract Full Text Full Text PDF PubMed Scopus (1100) Google Scholar), and so their low affinity for PUMA-G/HM74a and HM74 is probably not physiologically relevant. Consistent with this, while both HM74a/PUMA-G and GPR41 have similar chain length preferences, the latter receptor has at least 10-fold higher affinity for these acids (Table I and Ref. 20Xiong Y. Miyamoto N. Shibata K. Valasek M.A. Motoike T. Kedzierski R.M. Yanagisawa M. Proc. Natl. Acad. Sci. U. S. A. 2004; 101: 1045-1050Crossref PubMed Scopus (526) Google Scholar). We note as well that in another study racemic (dl)-β-OHB was not a GPR41 agonist at concentrations up to 10 mm (20Xiong Y. Miyamoto N. Shibata K. Valasek M.A. Motoike T. Kedzierski R.M. Yanagisawa M. Proc. Natl. Acad. Sci. U. S. A. 2004; 101: 1045-1050Crossref PubMed Scopus (526) Google Scholar). Similarly, another study found “l-OH-butyrate” (the exact molecular structure of which was not described) to be only a very weak (EC50 ∼5 mm) ligand of human GPR41 and GPR43, another receptor for short-chain fatty acids expressed predominantly in leukocytes (19Le Poul E. Loison C. Struyf S. Springael J.Y. Lannoy V. Decobecq M.E. Brezillon S. Dupriez V. Vassart G. Van Damme J. Parmentier M. Detheux M. J. Biol. Chem. 2003; 278: 25481-25489Abstract Full Text Full Text PDF PubMed Scopus (1100) Google Scholar). Finally, β-OHB was not an agonist of GPR81 (22Lee D.K. Nguyen T. Lynch K.R. Cheng R. Vanti W.B. Arkhitko O. Lewis T. Evans J.F. George S.R. O'Dowd B.F. Gene (Amst.). 2001; 275: 83-91Crossref PubMed Scopus (165) Google Scholar), the next most phylogenetically related receptor to HM74a/PUMA-G (data not shown). We employed an equilibrium [3H]nicotinic acid binding competition assay to ask whether nicotinic acid and β-OHB compete for the same binding site on the receptor. [3H]Nicotinic acid bound specifically and saturably to membranes from cells expressing HM74a, but not HM74 (data not shown), with a calculated Kd of 105 ± 9 nm (data not shown), a value in good agreement with published results (3Tunaru S. Kero J. Schaub A. Wufka C. Blaukat A. Pfeffer K. Offermanns S. Nat. Med. 2003; 9: 352-355Crossref PubMed Scopus (657) Google Scholar, 4Wise A. Foord S.M. Fraser N.J. Barnes A.A. Elshourbagy N. Eilert M. Ignar D.M. Murdock P.R. Steplewski K. Green A. Brown A.J. Dowell S.J. Szekeres P.G. Hassall D.G. Marshall F.H. Wilson S. Pike N.B. J. Biol. Chem. 2003; 278: 9869-9874Abstract Full Text Full Text PDF PubMed Scopus (460) Google Scholar). Homologous competition with unlabeled nicotinic acid yielded a Ki of 130 ± 14 nm, similar to the observed Kd (Fig. 1C). As in the [35S]GTPγS binding assay, AcAc displayed low apparent affinity for HM74a, but (dl)-β-OHB bound the receptor with physiologically relevant affinity (Ki = 0.7 ± 0.06 mm; Fig. 1C). Similar results were observed for PUMA-G (Ki = 0.7 mm ± 0.1 mm; data not shown). Taken together, these data show that (d)-β-OHB is a HM74a/PUMA-G agonist and that the serum concentrations of this ketone body observed as early as 2–3 days into a fast in humans (7Laffel L. Diabetes/Metabolism Res. Rev. 1999; 15: 412-426Crossref PubMed Google Scholar, 8Fukao T. Lopaschuk G.D. Mitchell G.A. Prostaglandins Leukotrienes Essent. Fatty Acids. 2004; 70: 243-251Abstract Full Text Full Text PDF PubMed Scopus (254) Google Scholar) will result in significant receptor occupancy and activity. Previous studies with isolated adipocytes from knock-out mice demonstrated that PUMA-G mediates the anti-lipolytic effect of nicotinic acid (3Tunaru S. Kero J. Schaub A. Wufka C. Blaukat A. Pfeffer K. Offermanns S. Nat. Med. 2003; 9: 352-355Crossref PubMed Scopus (657) Google Scholar); we performed analogous experiments with (d)-β-OHB. Both nicotinic acid and sodium (d)-β-OHB suppressed free fatty acid efflux from isoproterenol-stimulated primary adipocytes from wild-type mice, the latter at concentrations consistent with the affinity determined previously (approximate EC50 for (d)-β-OHB-mediated lipolysis inhibition ∼2 mm, Fig. 2A). This suppression was PUMA-G-mediated, as nicotinic acid and (d)-β-OHB were without significant effect in adipocytes from PUMA-G knock-out mice (Fig. 2B). Adipocytes from PUMA-G knock-out mice were not merely refractory to lipolysis inhibition per se, as ADP inhibited fatty acid efflux equally well in wild-type and knock-out cells (Fig. 2B). The adenosine analogue phenylisopropyladenosine also inhibited lipolysis equally well in wild-type and knock-out cells (data not shown). We note that the rate of both basal and isoproterenol-stimulated lipolysis was routinely lower in adipocytes from knock-out mice compared with those from wild-type animals (Fig. 2B; compare “No stimulation” and “Iso”). It is unlikely that this difference is due to a deficiency of lipid in the knockout adipocytes, as wild-type and knock-out cells had approximately the same overall size as determined by microscopy (data not shown), and wild-type and knock-out mice had the same overall fat mass as determined by NMR spectroscopy. 2D. Marsh, unpublished observations. In this work we have shown that the ketone body (d)-β-OHB specifically binds to and activates the adipocyte-expressed GPCRs HM74a/PUMA-G with an affinity that is well within the range of serum concentrations observed for this metabolite after ∼2–3 days of starvation in humans and ∼1–2 days in mice (7Laffel L. Diabetes/Metabolism Res. Rev. 1999; 15: 412-426Crossref PubMed Google Scholar, 10Cahill G.F. N. Engl. J. Med. 1970; 282: 668-675Crossref PubMed Google Scholar). The effect of (d)-β-OHB is, like nicotinic acid, anti-lipolytic (1Tavintharan S. Kashyap M.L. Curr. Atheroscler. Rep. 2001; 3: 74-82Crossref PubMed Scopus (87) Google Scholar, 2Carlson L.A. Acta Med. Scand. 1963; 173: 719-722Crossref PubMed Scopus (134) Google Scholar, 6Pike N.B. Wise A. Curr. Opin. Investig. Drugs. 2004; 5: 271-275PubMed Google Scholar). (d)-β-OHB is thus the first endogenous ligand described for the orphan receptor PUMA-G. During starvation, the rate of hepatic ketone body synthesis is at least partially limited by the rate of adipocyte lipolysis (7Laffel L. Diabetes/Metabolism Res. Rev. 1999; 15: 412-426Crossref PubMed Google Scholar). That (d)-β-OHB is itself anti-lipolytic suggests a homeostatic negative feedback mechanism in which this metabolite regulates its own production by decreasing the serum level of fatty acid precursors available for hepatic ketogenesis. Indeed, in a study of the serum NEFA-lowering effect of β-OHB infused into humans, Senior and Loridan (9Senior B. Loridan L. Nature. 1968; 219: 83-84Crossref PubMed Scopus (55) Google Scholar) proposed that during starvation ketone bodies exert “a fine regulatory adjustment” of their own synthesis by inhibiting adipocyte lipolysis. Such a mechanism would potentially conserve fat stores during extended starvation and attenuate excessive formation of ketoacids from unrestrained lipolysis and ketogenesis. This model implies that PUMA-G knock-out mice would experience higher rates of lipolysis and ketogenesis during a fast, as (d)-β-OHB does not inhibit lipolysis in the absence of this receptor. In preliminary experiments, we have not observed significant reproducible differences between wild-type and PUMA-G knock-out animals in rate of body fat depletion or serum levels of NEFA or (d)-β-OHB during 24 and 48 h of fasting. 3D. Marsh, M. Reitman, and A. Taggart, unpublished observations. However, we note that adipocytes from knock-out animals are refractory to stimulation with isoproterenol (Fig. 2B), perhaps suggesting a fundamental difference in lipolysis regulation in the knock-out cells that may compensate for lack of PUMA-G. Studies with inducible knock-outs of PUMA-G in adult animals may shed light on this question. We thank Steve Colletti of Merck Research Laboratories for synthesis of lithium (dl)-β-OHB; Graeme Semple and colleagues at Arena Pharmaceuticals for synthesis of Acifran; Sorin Tunaru of the University of Heidelberg for assistance with PUMA-G knock-out mice experiments; Donald Marsh, Kimberly Cox-York, and Marc Reitman for fasting studies with knock-out animals and advice; and Ismail Kola of Merck Research Laboratories for comments on the manuscript and support of this project.Keywords:
Puma
Hormone-sensitive lipase
Adipose triglyceride lipase
Cite
Citations (0)
▪ Abstract In vitro studies of adipocytes taken from different body fat regions suggest substantial differences in lipolysis between intra-abdominal, lower-body subcutaneous, and abdominal subcutaneous regions. Gender and obesity appear to influence these regional differences. In situ measurements of glycerol release from adipose tissue provided further evidence that regional heterogeneity of lipolysis occurs in humans. In vivo studies of regional free fatty acid (FFA) release have confirmed that adipose tissue lipolysis varies between upper- and lower-body fat. Release of FFA from lower-body adipose tissue is less than that from upper-body adipose tissue in both obese and non-obese men and women. In non-obese men and women, meal ingestion suppresses FFA release from all adipose tissue regions, and adrenergic stimulation activated FFA release from different sites in a gender-specific fashion. Significant regional and gender differences in adipose tissue lipolysis occur in humans, and this could contribute to differences in the health effects of adipose tissue and could theoretically influence body fat distribution.
Cite
Citations (156)
Adipose tissue macrophages
ACTH receptor
Cite
Citations (29)
Basal (medicine)
Cite
Citations (10)
Lipolysis in human adipose tissue was measured as glycerol release in isolated fat cells and in adipose tissue homogenates. In isolated fat cells lipolysis proceeded optimally at pH 7.4, was stimulated 3.5 fold by noradrenaline and was not influenced by serum or protamine. In adipose tissue homogenates lipolysis was stimulated 4 fold by serum. Serum-stimulated lipolytic activity was optimal at pH 8.0, was inhibited by 1 M sodium chloride and protamine and was not influenced by noradrenaline. Lipolytic activity in isolated fat cells is ascribed on the basis of these observations mainly to the action of hormone-sensitive lipase. whereas lipolysis in adipose tissue homogenates in the presence of serum seems to be regulated by lipoprotein lipase. Thus, the lipolytic processes involved in the mobilization of triglycerides from adipose tissue and in the uptake or triglycerides into adipose tissue can be assessed separately, using the two described methods. The re-esterification of FFA, the second pathway in the mobilization of triglycerides, has also been investigated.
Adipose tissue macrophages
Cite
Citations (0)
In sepsis and endotoxemia, metabolism is characterized by accelerated catabolism. In the present study, lipolytic responsiveness of subcutaneous and mesenteric adipose tissue to the sub-lethal dose of endotoxin injection (5 mg/kg) was evaluated using microdialysis techniques in rats. All rats were urethane-anesthetized and implanted with microdialysis probes in their subcutaneous and mesenteric adipose tissue. Lipolysis in each adipose tissue was assessed by measuring the glycerol concentration (an index of lipolysis) in the dialysate from the microdialysis probe. Lipolysis was continuously monitored for 7-hours, prior to and following the injection of endotoxin. The control animals were injected with only saline. Lipolysis in subcutaneous adipose tissue began to increase by 1-hours after endotoxin injection, and reached a peak 60% higher than the basal level by 2-hours after injection. This activated lipolysis after endotoxin was markedly greater than that in the control animals and maintained for 5 hours. In mesenteric adipose tissue, lipolysis after endotoxin injection was greater than in the control animals, but not significant. The endotoxin-induced lipolysis in the subcutaneous adipose tissue was significantly greater than that in the mesenteric adipose tissue. We conclude that the sub-lethal dose of endotoxin injection cause active lipolysis in adipose tissues, and that the lipolytic responsiveness to endotoxin in subcutaneous adipose tissue is greater than in mesenteric adipose tissue.
Microdialysis
Catabolism
Subcutaneous tissue
Cite
Citations (10)
NEFA
Cite
Citations (1)
Abstract One of the primary metabolic functions of a mature adipocyte is to supply energy via lipolysis, or the catabolism of stored lipids. Hormone-sensitive lipase (HSL) is a critical lipolytic enzyme, and its phosphorylation and subsequent activation by PKA generates phospho-binding sites for 14-3-3 proteins, a ubiquitously expressed family of molecular scaffolds. While we previously identified essential roles of the 14-3-3ζ isoform in murine adipogenesis, the presence of 14-3-3 protein binding sites on HSL suggests that 14-3-3ζ could also influence mature adipocyte processes like lipolysis. Herein, we demonstrate that 14-3-3ζ is necessary for lipolysis in male mice and fully differentiated 3T3-L1 adipocytes, as depletion of 14-3-3ζ significantly impaired glycerol and FFA release. Unexpectedly, this was not due to impairments in signaling events underlying lipolysis; instead, reducing 14-3-3ζ expression was found to significantly impact adipocyte maturity, as observed by reduced abundance of PPARγ2 protein and expression of mature adipocytes genes and those associated with de novo triglyceride synthesis and lipolysis. The impact of 14-3-3ζ depletion on adipocyte maturity was further examined with untargeted lipidomics, which revealed that reductions in 14-3-3ζ abundance promoted the acquisition of a lipidomic signature that resembled undifferentiated, pre-adipocytes. Collectively, these findings reveal a novel aspect of 14-3-3ζ in adipocytes, as reducing 14-3-3ζ was found to have a negative effect on adipocyte maturity and adipocyte-specific processes like lipolysis.
Adipose triglyceride lipase
Lipid droplet
Perilipin
Catabolism
Hormone-sensitive lipase
Cite
Citations (0)
Subcutaneous adipose tissue
Basal (medicine)
Subcutaneous fat
Tissue sample
Cite
Citations (5)
Lipolytic response to conditions producing alterations in carbohydrate metabolism was tested on human newborn subcutaneous adipose tissue <i>in vitro</i>. Glycerol release from intact adipose tissue fragments or n isolated adipose tissue cells was used to indicate the rate of lipolysis. The addition of glucose increased glycerol release in isolated cells (p < 0.01–0.025) and in intact tissue fragments (p < 0.0005–0.0025) from subcutaneous adipose tissue in neonates, but did not affect the glycerol release in the same tissue in adults. Lipolysis was also significantly increased after addition of pyruvate (p < 0.025). Oligomycin and reduced oxygen tension diminished the stimulatory effect of glucose on lipolysis. Basal glycerol release was often elevated in newborns in whom the adipose tissue glycogen content was higher than in normal newborn infants of the same age.
Subcutaneous adipose tissue
Carbohydrate Metabolism
Perilipin
Cite
Citations (10)